9月9日 - ** 药物开发商 Anavex Life Sciences AVXL.O 股价盘前上涨 2.7% 至 9.60 美元
** 该公司称其阿尔茨海默氏症试验性药物blarcamesine (link) 在中晚期试验中经过48周的治疗后减缓了早期患者的记忆力衰退
** 该公司称，在试验中每天服用30毫克剂量barcamesine的患者在主要认知测试中表现出 "几乎检测不到 "的衰退
** 布拉卡米辛是一种每日一次的口服药物，它通过激活蛋白质SIGMAR1来帮助清除大脑中受损的蛋白质，从而减缓早期阿尔茨海默氏症患者认知能力的下降。
** 截至上一交易日收盘，股价累计下跌 13
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.